PolyMedix announced its Phase 2 study of PMX-60056 for the treatment of reversing heparin in patients undergoing PCI procedures. This multicenter, open-label clinical study is intended to enroll up to 40 patients undergoing PCI in the U.S. The primary efficacy endpoint is to evaluate the safety and efficacy of PMX-60056 in reversing heparin in a surgical setting such as PCI.
PMX-60056 is a synthetic, small molecule designed to reverse the anticoagulation activity of heparin and low molecular weight heparins.
For more information call (484) 598-2340 or visit www.polymedix.com.